Literature DB >> 3933518

Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells.

X Emonds-Alt, J C Brelière, R Roncucci.   

Abstract

Articular chondrocytes and synovial cells were stimulated to produce collagenase, neutral casein and proteoglycan-degrading proteinases by conditioned medium from human peripheral blood mononuclear cells. Collagenase, neutral casein and proteoglycan-degrading proteinase secretion was inhibited by SR 41319, a new bisphosphonate, in a concentration-dependent manner. Complete inhibition was achieved at about 0.3 mM. EHDP exhibited the same general profile but was about 10-fold less active and never completely inhibited the enzyme secretion. When added before MCF, SR 41319 had a protective effect against subsequent activation of the cells by MCF. SR 41319 also inhibited the increase of enzyme secretion by cells previously stimulated with MCF. The results suggest that the ability of SR 41319 to inhibit the MCF-mediated secretion of neutral enzymes involved in cartilage destruction could be valuable in the management of connective tissue damage in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933518     DOI: 10.1016/0006-2952(85)90385-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake.

Authors:  M J Rogers; X Xiong; X Ji; J Mönkkönen; R G Russell; M P Williamson; F H Ebetino; D J Watts
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

2.  Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate.

Authors:  M Audran; P Clochon; D Etghen; B Mazieres; J C Renier
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

3.  Paget's disease of bone treated with a five day course of oral tiludronate.

Authors:  J Y Reginster; M P Lecart; R Deroisy; D Ethgen; B Zegels; P Franchimont
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

4.  Effects of low and high dose intraarticular tiludronate on synovial fluid and clinical variables in healthy horses-a preliminary investigation.

Authors:  Katja F Duesterdieck-Zellmer; Lindsey Moneta; Jesse F Ott; Maureen K Larson; Elena M Gorman; Barbara Hunter; Christiane V Löhr; Mark E Payton; Jeffrey T Morré; Claudia S Maier
Journal:  PeerJ       Date:  2014-09-04       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.